|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-10-4
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The current standard of care for patients with chronic hepatitis C virus (HCV) genotype 1 is once-weekly pegylated interferon-? (Peg-IFN?) plus daily ribavirin for 48 weeks. We evaluated the efficacy/safety of albinterferon alfa-2b (albIFN), a novel, long-acting, genetic fusion polypeptide of albumin and IFN?-2b.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1528-0012
|
|
pubmed:author |
pubmed-author:ACHIEVE-1 Study Team,
pubmed-author:BaconBruce RBR,
pubmed-author:CianciaraJanuszJ,
pubmed-author:CroninPatrick WPW,
pubmed-author:GrigorescuMirceaM,
pubmed-author:LawitzEric JEJ,
pubmed-author:LurieYoavY,
pubmed-author:McHutchisonJohn GJG,
pubmed-author:MuirAndrew JAJ,
pubmed-author:PulkstenisErikE,
pubmed-author:Rodriguez-TorresMaribelM,
pubmed-author:RustgiVinod KVK,
pubmed-author:SubramanianG ManiGM,
pubmed-author:SulkowskiMark SMS,
pubmed-author:TiceAlan DAD,
pubmed-author:ZeuzemStefanS
|
|
pubmed:copyrightInfo |
Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
139
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1257-66
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20600013-Adult,
pubmed-meshheading:20600013-Albumins,
pubmed-meshheading:20600013-Antiviral Agents,
pubmed-meshheading:20600013-Drug Therapy, Combination,
pubmed-meshheading:20600013-Female,
pubmed-meshheading:20600013-Hepatitis C, Chronic,
pubmed-meshheading:20600013-Humans,
pubmed-meshheading:20600013-Interferon-alpha,
pubmed-meshheading:20600013-Male,
pubmed-meshheading:20600013-Middle Aged,
pubmed-meshheading:20600013-Polyethylene Glycols,
pubmed-meshheading:20600013-Recombinant Proteins,
pubmed-meshheading:20600013-Ribavirin
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Albinterferon Alfa-2b was not inferior to pegylated interferon-? in a randomized trial of patients with chronic hepatitis C virus genotype 1.
|
|
pubmed:affiliation |
JW Goethe University Hospital, Frankfurt, Germany. zeuzem@em.uni-frankfurt.de
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
